Narrow-band ultraviolet B therapy for Metastatic cancers: Narrow-band ultraviolet B increases the expression of metastasis suppressors BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 11/June/2017, 12.35 am

Anti-telomerase cancer therapy: USF-1 (Upstream Transcription Factor 1) suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 11/June/2017, 12.30 am
June 10, 2017
Natural product therapy for KRAS/LKB1-mutant lung cancer: Epigallocatechin gallate (EGCG), isolated from Green tea, increases the levels of tumor suppressor proteins, inhibits the expression of urea cycle enzyme carbamoyl phosphate synthetase-1 (CSP1), decreases pyrimidine pools, stalls DNA synthesis, and inhibits the progression of KRAS/LKB1-mutated lung cancers via up regulation of its target gene, 11/June/2017, 11.46 pm
June 11, 2017
Show all

From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

A number of studies suggests that Narrow-band ultraviolet B inhibits tumor cell proliferation. However, the mechanism of action is far from clear.

This study suggests that Narrow-band ultraviolet B, by regulating the expression of its target genes, it may increase the expression of metastasis suppressors BTG2 and INK4a (fig. 1).

[easy_payment currency=”USD”]

Thereby, it may: (a) inhibit cell cycle progression; and (d) suppress migration, invasion and metastasis of cancer cells. 

Thus,  Narrow-band ultraviolet B-based therapy may be advised for metastatic cancer patients to (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy. Together, oncologists may consider adapting  Narrow-band ultraviolet B-based therapy in the treatment of Cancer.


Details of the research findings

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $10

Undisclosed mechanistic information: How Narrow-band ultraviolet B increases the expression of metastasis suppressors   BTG2 and INK4a

Fig1. Mechanistic insights into how Narrow-band ultraviolet B functions as an anti-metastasis agent. Narrow-band ultraviolet B increases the expression of metastasis suppressors BTG2 and INK4a via down regulation of its target genes.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org


References

CitationBoominathan, L., Narrow-band ultraviolet B therapy for Metastatic cancers: Narrow-band ultraviolet B  increases the expression of metastasis suppressors BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 11/June/2017, 12.35 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.